AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (1.1 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

Targeting MUC1 with fisetin in oral squamous cell carcinoma

Qian Wanga,1Hongyan Zhangb,c,1Shuzhen XiangaLan ZhangaJiajia FanaZengyan Xub,cFengfei Zhaob,cMinda Liua( )Yanshu Lib,c( )Wei Daia( )
Department of Oral Maxillofacial-Head and Neck Surgery, School of Stomatology, China Medical University, Oral Diseases Laboratory of Liaoning, Shenyang, Liaoning 110000, China
Department of Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health, China Medical University, Shenyang, Liaoning 110122, China
Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, Liaoning 110122, China

Peer review under the responsibility of the Genes & Diseases Editorial Office, in alliance with the Association of Chinese Americans in Cancer Research (ACACR, Baltimore, MD, USA).

1 These authors contributed equally to this work.

Show Author Information

References

【1】
【1】
 
 
Genes & Diseases
Article number: 101357

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Wang Q, Zhang H, Xiang S, et al. Targeting MUC1 with fisetin in oral squamous cell carcinoma. Genes & Diseases, 2025, 12(3): 101357. https://doi.org/10.1016/j.gendis.2024.101357

366

Views

1

Downloads

1

Crossref

2

Web of Science

0

Scopus

0

CSCD

Received: 20 December 2023
Published: 20 June 2024
© 2025 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).